Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure

This publication has 18 references indexed in Scilit:

• Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure
  Published by Elsevier ,2010
• Hemodynamic, renal, and neurohumoral effects of a selective oral DA1 receptor agonist (fenoldopam) in patients with congestive heart failure
  American Heart Journal, 1988
• The Effect of Selective Dopamine-1 Receptor Stimulation on Renal and Adrenal Function in Man*
  Journal of Clinical Endocrinology & Metabolism, 1988
• Intravenous fenoldopam in heart failure: Comparing the hemodynamic effects of dopamine1 receptor agonism with nitroprusside
  American Heart Journal, 1988
• Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam.
  Circulation, 1987
• The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro.
  British Journal of Clinical Pharmacology, 1986
• Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure
  Journal of the American College of Cardiology, 1985
• Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension.
  Journal of Clinical Investigation, 1984
• Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension.
  Circulation, 1984
• Alterations in vasomotor tone in congestive heart failure
  Progress in Cardiovascular Diseases, 1982